Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference
November 25 2019 - 07:00AM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical
dermatology company committed to the development and
commercialization of novel treatments that provide meaningful
benefit for people living with skin diseases, today announced that
Ted White, Verrica President and CEO, will participate in a
fireside chat at the Piper Jaffray 31st Annual Healthcare
Conference in New York, NY on Tuesday, December 3, 2019 at 11:00
a.m. ET.
About Verrica Pharmaceuticals Inc.
Verrica is a medical dermatology company committed to the
development and commercialization of novel treatments that provide
meaningful benefit for people living with skin diseases. The
Company’s late-stage product candidate, VP-102, is a potential
first-in-class topical therapy for the treatment of molluscum
contagiosum and common warts. Molluscum is a highly contagious
viral skin infection affecting approximately six million people,
primarily children, in the United States, and common warts are
contagious skin growths affecting 22 million people. There are
currently no FDA-approved treatments for molluscum or common
warts. Following positive topline results from two pivotal Phase 3
trials, the Company submitted an NDA in September 2019 for VP-102
for the treatment of molluscum. Verrica is planning to meet with
the FDA to determine next steps on the development of
VP-102 for common warts following positive Phase 2 results. VP-102
is also currently in a Phase 2 trial for the treatment of external
genital warts. A second product candidate, VP-103, is in
pre-clinical development for plantar warts. For more information,
visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will,” and
similar expressions, and are based on Verrica’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the potential benefits of VP-102 for the treatment of
molluscum and the clinical development of VP-102 for additional
indications, including common warts, external genital warts and
plantar warts. These statements involve risks and uncertainties
that could cause actual results to differ materially from those
reflected in such statements. Risks and uncertainties that may
cause actual results to differ materially include uncertainties
inherent in the drug development process and the regulatory
approval process, Verrica’s reliance on third parties over which it
may not always have full control, and other risks and uncertainties
that are described in Verrica’s Annual Report on Form 10-K for the
year ended December 31, 2018, filed with the U.S. Securities and
Exchange Commission on March 7, 2019, and other filings Verrica
makes with the U.S. Securities and Exchange Commission. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Verrica as of the
date of this release, and Verrica assumes no obligation to, and
does not intend to, update any forward-looking statements, whether
as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE
CONTACT:
Investors:
A. Brian DavisChief Financial
Officer484.453.3300 ext. 103info@verrica.com
Chiara RussoSolebury
Trout617.221.9197crusso@soleburytrout.com
Media:
Joshua R. MansbachSolebury
Trout646-378-2964jmansbach@troutgroup.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2023 to Mar 2024